Therefore, we can speculate that impairment of β-oxidation and the resultant metabolism may lead to therapy sensitivity although promising approach to increase sensitivity of HER2-positive breast cancers to targeted therapy is proposed42. This evidence concerns the gene ERBB2 and breast carcinoma.